EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients. EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for a pipeline asset. EffRx is a member of the World Orphan Drug Alliance (WODA). WODA provides full-service solution to pharmaceutical & biotech companies with a portfolio of rare diseases, oncology and highly specialized therapeutics, starting from named patient programs to full commercialization. WODA covers 68 countries in the following regions: - Central and Eastern Europe (Medis) - Latin America (OrphanDC) - Middle East, North Africa & Turkey (Vector Pharma) - Russia & the CIS region (Orpharm) - Switzerland (EffRx Pharmaceuticals)